Idiopathic Pulmonary Fibrosis (IPF) is a devastating lung disease affecting millions worldwide, with a grim prognosis of only three to five years post-diagnosis. In this episode, leading lung disease expert Victor Thannickal, MD, delves into the symptoms, progression, and impacts of IPF. He also sheds light on promising new drug therapies emerging from his lab, offering hope in the fight against this relentless disease. Host Elaine Hamm, PhD, skillfully navigates the complex landscape of IPF, making this a must-listen for anyone interested in cutting-edge biotech developments.
If you enjoyed the episode, please consider liking, sharing, and subscribing to BIO from the BAYOU. Your support helps us continue delivering high-quality content to listeners passionate about the biotech industry.
Links:
Connect with
Victor Thannickal, MD.
Check out the
Tulane Medicine Magazine, which provides more details on Tulane’s fight against IPF.
Connect with
Elaine Hamm, PhD.
Learn about
Tulane Medicine Business Development and the
School of Medicine.
Check out
BIO on the BAYOU and make plans to attend October 29 & 30, 2024.
Learn more about
BIO from the BAYOU – the podcast, the upcoming event, and more!
Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.